News Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Delayed Japan Exchange Other stock markets 09:25:29 27/06/2024 am IST			5-day change	1st Jan Change
1,622 ^JPY	-2.20%		+1.15%	+15.52%

10/05	Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	MT
09/05	Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Santen Pharmaceutical : Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan	22/05	PU
Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	10/05	MT
Santen Pharmaceutical : Announces Share Buyback	09/05	PU
Santen Pharmaceutical : Reports Fiscal 2023 Consolidated Performance	09/05	PU
Santen Pharmaceutical : Notice of Board of Director and Corporate Auditor Nominations	09/05	PU
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	09/05	CI
Santen Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2025	09/05	CI
Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2024, Payable on June 26, 2024; Provides Dividend Guidance for the End of Second Quarter of 2025	09/05	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025	09/05	CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	09/05	CI
Santen Pharmaceutical : and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis	07/05	PU
Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	17/04	PU
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	16/04	PU
Final dividend	28/03	FA
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	26/03	PU
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	26/03	MT
Santen Pharmaceutical : Announces Change of Representative Director of the Board	25/03	PU
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	25/03	PU
Santen Pharmaceutical : Announces Completion of Share Buyback	25/03	PU
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	25/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Summary

Filters